Procter & Gamble Hygiene and Health Care Limited has informed the Exchange about Transcript and Link of Recording
PGHH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
P&G Hygiene shared results for the 9-month fiscal year ended March 31, 2025 (financial year changed to April-March): sales of Rs 3,374 crore, up 3% year-on-year, and profit after tax of Rs 636 crore, up 7%. The company highlighted Rs 93 crore in productivity savings (doubled from the prior period), structural margin improvement of about 250 basis points over five years, and a 60 basis point net margin expansion this year despite mid-single-digit cost inflation. Management detailed innovation across Whisper (Period Pants, Ultra XL, Choice upgrades) and Vicks (Cough Syrup, Steam Pods, Double Power Drops, ZzzQuil), and noted distribution expansion of 1 million stores over three years. On outlook, the CFO struck a cautiously optimistic tone, flagging rural demand recovery but persistent weakness in urban India. The company chose not to comment on a recent P&G global announcement, future product launches, or potential acquisitions.
Steady, in-line results with continued margin expansion should reassure investors, though the cautious view on urban demand and evasion of questions around the global P&G announcement may temper enthusiasm. The stock likely to see a neutral-to-mildly-positive reaction given the predictable execution track record.